glp 1 with hashimoto's disease Can a patient thyroiditis safely be treated with a GLP‑1 receptor agonist (e.g., liraglutide, semaglutide, dulaglutide)? Implications of GLP-1 Receptor Agonist

[8] Novo Nordisk announced late at the 2025 European Association for the Study of Diabetes (EASD) annual meeting that in the REDEFINE 1 study, [9] cagrilintide provided clinically significant weight loss, with a mean reduction in body weight of 11.8% compared to 2.3% with placebo after 68 weeks, considering adherence of all participants to treatment

A more conservative approach may be worth discussing with a provider if you have a history of GI sensitivity or conditions like IBS, have previously stopped GLP-1 therapy because of side effects, are an older adult (who may be more sensitive to GI effects), or are starting treatment at a lower BMI where the full therapeutic dose may not be necessary

The sweet spot for most researchers using a 5mg vial is 1.0mL of bacteriostatic water

After seven weeks, the group that received the diet without supplemental L-carnitine lost 1.8% body weight compared to 6.4% body weight loss from the group that was fed the L-carnitine supplemented diet

Some people may experience mild digestive upset, such as nausea or bloating, especially when taking high doses on an empty stomach

They are NOT medications